APHIOS® PRESENTS ITS COMBINATION THERAPY FOR TREATING HIV LATENCY AT THE 6TH INTERNATIONAL AIDS SOCIETY CONFERENCE IN ROME, ITALY

September 21, 2011

Woburn, Mass. – July 19, 2011 –Dr. Trevor P. Castor, President and CEO of Aphios® Corporation, presented a Combination Therapy for Treating HIV Latency at the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy.

More than 5,000 AIDS researchers, scientists, clinicians, community leaders and policy experts from around the globe gathered at the Auditorium Parco della Musica, Rome, Italy, to attend the three-day IAS Conference, which is the world’s largest open scientific conference on HIV/AIDS.  The use of HIV treatment as prevention was the major theme of the conference, but some important research on new approaches to treating and/or curing HIV/AIDS were also presented including the National Association of People With AIDS (NAPWA) satellite symposium “NAPWA’s Treatment Horizons: Pathways to a Functional Cure,” in which Dr. Castor presented APH-0812, a combination therapy as a potential cure for HIV/AIDS.

“Over the last decade, Highly Active Anti-Retroviral Therapy (HAART) has been a lifesaver for millions of patients with HIV/AIDS,” explained Dr. Castor.  “Unfortunately, upon removal of HARRT, the virus rebounds from latent HIV-infected cellular reservoirs. HIV latency complicates the quality of lives of HIV patients who suffer through multi-component drug regimens, some of which they become resistant to and which often have significant side effects and toxicities.”

“For these and related economic reasons, eradication of HIV virus reservoirs can be a major step in curing HIV/AIDS and halting this epidemic,” Dr. Castor continued. “We at Aphios® with our Spanish collaborators at Universidad de Córdoba, Ramon y Cajal Hospital, Madrid, and VivaCell Biotechnology, España, are investigating a combination therapy that includes a Protein Kinase C (PKC) modulator which down regulates the expression of the HIV-1 receptors CD4 and CXCR4 and thus is a candidate for treating HIV-1 latency. Our researchers have also discovered that nanomolar concentrations of this PKC modulator synergize with histone deacetylase (HDAC) inhibitors to antagonize HIV-1 latency.” Aphios® hopes to announce a Phase I/II human clinical trial of APH-0812 in Spain later this year or early in 2012.

Woburn, MA, based Aphios® Corporation is a green biotechnology company developing enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, Aphios® is developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases such as HIV and influenza, and central nervous system disorders such as Alzheimer’s Disease.

Founded in 1983 as the largest and oldest advocacy group for people living with HIV/AIDS, The National Association of People With AIDS (NAPWA) is the trusted independent voice for all people living with the virus in the United States.  NAPWA remains a strong voice in policy, capacity building, leadership development, and social networking. NAPWA is a 501(c) 3 non-profit organization based in Silver Spring, MD.  For more information about NAPWA, please visit www.napwa.org.

The International AIDS Society (IAS) is the world’s largest leading independent association of HIV professionals, with over 13,000 members in 188 countries working at all levels of the global response to HIV/AIDS.  IAS members represent scientists, clinicians, public health and community practitioners on the frontlines of the epidemic. The IAS is the custodian of the biennial International AIDS Conference and the host of the IAS Conference on HIV Pathogenesis, Treatment and Prevention. For more information about IAS, please visit www.iasociety.org.

###

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.